Corrigendum

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Cervical cancer remains a significant global health challenge, often driven by persistent infection with high-risk human papillomavirus (HPV).
• The HPV E6 and E7 oncoproteins are critical in the pathogenesis of cervical cancer, promoting cellular transformation and inhibiting apoptosis.
• Novel therapeutic strategies targeting these oncogenes are urgently needed.

Purpose of the Study:

• To investigate the anti-cancer effects of organosulphur compounds on cervical cancer cells.
• To determine the mechanism by which these compounds exert their effects, specifically focusing on the downregulation of HPV E6 and E7 oncogenes.
• To evaluate the potential of organosulphur compounds as therapeutic agents for cervical cancer.

Main Methods:

• In vitro studies using cervical cancer cell lines.
• Treatment with various organosulphur compounds.
• Assessment of apoptosis induction using assays like Annexin V/PI staining.
• Cell cycle analysis via flow cytometry.
• Evaluation of HPV E6 and E7 oncogene expression levels using techniques such as RT-PCR or Western blotting.

Main Results:

• Organosulphur compounds demonstrated significant induction of apoptosis in cervical cancer cells.
• These compounds effectively caused cell cycle arrest at specific phases.
• A notable downregulation of HPV E6 and E7 oncogene expression was observed following treatment.
• The findings suggest a direct link between organosulphur compounds and the inhibition of key viral oncoproteins.

Conclusions:

• Organosulphur compounds possess potent anti-cancer properties against cervical cancer cells.
• The mechanism involves the induction of apoptosis and cell cycle arrest, mediated by the downregulation of HPV E6 and E7.
• These findings highlight the therapeutic potential of organosulphur compounds in cervical cancer treatment.